Treatment of advanced renal cell carcinoma with IFN-α, VLB and UFT

T. Saika, K. Kobashi, T. Tsushima, Yasutomo Nasu, M. Noda, H. Ohmori, Y. Matsumura, T. Akaeda, M. Hara, N. Ike, K. Kondo, T. Asahi, M. Saegusa, T. Johsen

Research output: Contribution to journalArticle

Abstract

The therapeutic efficacy of immuno-chemotherapy was evaluated in patients with advanced renal cell carcinoma. Fifteen patients received induction therapy, a combination of human lymphoblastoid interferon (HLBI) (3 x 106 IU, i.m. every day) plus vinblastine (VLB) (3mg/m2, i.v. once a week) with (Group A) or without (Group B) UFT (a compound of Tegafur and uracil) (300mg/body, p.o. every day), and maintenance therapy, a combination of HLBI (3 x 106 IU, i.m. 3 days a week) plus VLB (3mg/m2, i.v. once a month) with (Group A) or without (Group B) UFT (300mg/body, p.o. every day). Twelve patients (6 of Group A and 6 of Group B) were evaluable for their response to the treatment. There were no patients who showed a complete response (CR). One patient of Group A (8% of overall) experienced a partial response (PR), while 2 of Group A, and 1 of Group B showed a minor response (MR). The response duration of PR patients was 8 months. Toxicity was evaluable in 13 patients. Anorexia, general fatigue and leukopenia were most common, and these were observed in about 70% of patients. In addition, one patient withdrew from the trial because of anal bleeding. The average duration of survival was 10.0 months. Our results suggest that combination immunochemotherapy with HLBI, VLB and UFT for advanced renal cell carcinoma is not excellent when compared with HLBI alone.

Original languageEnglish
Pages (from-to)127-131
Number of pages5
JournalNishinihon Journal of Urology
Volume56
Issue number2
Publication statusPublished - 1994

Fingerprint

Renal Cell Carcinoma
Interferon-alpha
Therapeutics
Tegafur
Uracil
Vinblastine
Leukopenia
Anorexia
Fatigue
Hemorrhage
Drug Therapy
Survival

ASJC Scopus subject areas

  • Urology

Cite this

Saika, T., Kobashi, K., Tsushima, T., Nasu, Y., Noda, M., Ohmori, H., ... Johsen, T. (1994). Treatment of advanced renal cell carcinoma with IFN-α, VLB and UFT. Nishinihon Journal of Urology, 56(2), 127-131.

Treatment of advanced renal cell carcinoma with IFN-α, VLB and UFT. / Saika, T.; Kobashi, K.; Tsushima, T.; Nasu, Yasutomo; Noda, M.; Ohmori, H.; Matsumura, Y.; Akaeda, T.; Hara, M.; Ike, N.; Kondo, K.; Asahi, T.; Saegusa, M.; Johsen, T.

In: Nishinihon Journal of Urology, Vol. 56, No. 2, 1994, p. 127-131.

Research output: Contribution to journalArticle

Saika, T, Kobashi, K, Tsushima, T, Nasu, Y, Noda, M, Ohmori, H, Matsumura, Y, Akaeda, T, Hara, M, Ike, N, Kondo, K, Asahi, T, Saegusa, M & Johsen, T 1994, 'Treatment of advanced renal cell carcinoma with IFN-α, VLB and UFT', Nishinihon Journal of Urology, vol. 56, no. 2, pp. 127-131.
Saika T, Kobashi K, Tsushima T, Nasu Y, Noda M, Ohmori H et al. Treatment of advanced renal cell carcinoma with IFN-α, VLB and UFT. Nishinihon Journal of Urology. 1994;56(2):127-131.
Saika, T. ; Kobashi, K. ; Tsushima, T. ; Nasu, Yasutomo ; Noda, M. ; Ohmori, H. ; Matsumura, Y. ; Akaeda, T. ; Hara, M. ; Ike, N. ; Kondo, K. ; Asahi, T. ; Saegusa, M. ; Johsen, T. / Treatment of advanced renal cell carcinoma with IFN-α, VLB and UFT. In: Nishinihon Journal of Urology. 1994 ; Vol. 56, No. 2. pp. 127-131.
@article{f6504c093b1640c79edbcc100ca9c166,
title = "Treatment of advanced renal cell carcinoma with IFN-α, VLB and UFT",
abstract = "The therapeutic efficacy of immuno-chemotherapy was evaluated in patients with advanced renal cell carcinoma. Fifteen patients received induction therapy, a combination of human lymphoblastoid interferon (HLBI) (3 x 106 IU, i.m. every day) plus vinblastine (VLB) (3mg/m2, i.v. once a week) with (Group A) or without (Group B) UFT (a compound of Tegafur and uracil) (300mg/body, p.o. every day), and maintenance therapy, a combination of HLBI (3 x 106 IU, i.m. 3 days a week) plus VLB (3mg/m2, i.v. once a month) with (Group A) or without (Group B) UFT (300mg/body, p.o. every day). Twelve patients (6 of Group A and 6 of Group B) were evaluable for their response to the treatment. There were no patients who showed a complete response (CR). One patient of Group A (8{\%} of overall) experienced a partial response (PR), while 2 of Group A, and 1 of Group B showed a minor response (MR). The response duration of PR patients was 8 months. Toxicity was evaluable in 13 patients. Anorexia, general fatigue and leukopenia were most common, and these were observed in about 70{\%} of patients. In addition, one patient withdrew from the trial because of anal bleeding. The average duration of survival was 10.0 months. Our results suggest that combination immunochemotherapy with HLBI, VLB and UFT for advanced renal cell carcinoma is not excellent when compared with HLBI alone.",
author = "T. Saika and K. Kobashi and T. Tsushima and Yasutomo Nasu and M. Noda and H. Ohmori and Y. Matsumura and T. Akaeda and M. Hara and N. Ike and K. Kondo and T. Asahi and M. Saegusa and T. Johsen",
year = "1994",
language = "English",
volume = "56",
pages = "127--131",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "2",

}

TY - JOUR

T1 - Treatment of advanced renal cell carcinoma with IFN-α, VLB and UFT

AU - Saika, T.

AU - Kobashi, K.

AU - Tsushima, T.

AU - Nasu, Yasutomo

AU - Noda, M.

AU - Ohmori, H.

AU - Matsumura, Y.

AU - Akaeda, T.

AU - Hara, M.

AU - Ike, N.

AU - Kondo, K.

AU - Asahi, T.

AU - Saegusa, M.

AU - Johsen, T.

PY - 1994

Y1 - 1994

N2 - The therapeutic efficacy of immuno-chemotherapy was evaluated in patients with advanced renal cell carcinoma. Fifteen patients received induction therapy, a combination of human lymphoblastoid interferon (HLBI) (3 x 106 IU, i.m. every day) plus vinblastine (VLB) (3mg/m2, i.v. once a week) with (Group A) or without (Group B) UFT (a compound of Tegafur and uracil) (300mg/body, p.o. every day), and maintenance therapy, a combination of HLBI (3 x 106 IU, i.m. 3 days a week) plus VLB (3mg/m2, i.v. once a month) with (Group A) or without (Group B) UFT (300mg/body, p.o. every day). Twelve patients (6 of Group A and 6 of Group B) were evaluable for their response to the treatment. There were no patients who showed a complete response (CR). One patient of Group A (8% of overall) experienced a partial response (PR), while 2 of Group A, and 1 of Group B showed a minor response (MR). The response duration of PR patients was 8 months. Toxicity was evaluable in 13 patients. Anorexia, general fatigue and leukopenia were most common, and these were observed in about 70% of patients. In addition, one patient withdrew from the trial because of anal bleeding. The average duration of survival was 10.0 months. Our results suggest that combination immunochemotherapy with HLBI, VLB and UFT for advanced renal cell carcinoma is not excellent when compared with HLBI alone.

AB - The therapeutic efficacy of immuno-chemotherapy was evaluated in patients with advanced renal cell carcinoma. Fifteen patients received induction therapy, a combination of human lymphoblastoid interferon (HLBI) (3 x 106 IU, i.m. every day) plus vinblastine (VLB) (3mg/m2, i.v. once a week) with (Group A) or without (Group B) UFT (a compound of Tegafur and uracil) (300mg/body, p.o. every day), and maintenance therapy, a combination of HLBI (3 x 106 IU, i.m. 3 days a week) plus VLB (3mg/m2, i.v. once a month) with (Group A) or without (Group B) UFT (300mg/body, p.o. every day). Twelve patients (6 of Group A and 6 of Group B) were evaluable for their response to the treatment. There were no patients who showed a complete response (CR). One patient of Group A (8% of overall) experienced a partial response (PR), while 2 of Group A, and 1 of Group B showed a minor response (MR). The response duration of PR patients was 8 months. Toxicity was evaluable in 13 patients. Anorexia, general fatigue and leukopenia were most common, and these were observed in about 70% of patients. In addition, one patient withdrew from the trial because of anal bleeding. The average duration of survival was 10.0 months. Our results suggest that combination immunochemotherapy with HLBI, VLB and UFT for advanced renal cell carcinoma is not excellent when compared with HLBI alone.

UR - http://www.scopus.com/inward/record.url?scp=0028265976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028265976&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028265976

VL - 56

SP - 127

EP - 131

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 2

ER -